Target Audience
- Researchers and scientists familiar with genomic technologies such as next-generation sequencing (NGS) and microarrays who are interested in how these technologies became the foundation of a major industry.
- Readers interested in Illumina's corporate history, product strategy, technology acquisitions, mergers and acquisitions (M&A), and leadership transitions.
- Anyone interested in the competitive dynamics of the genomics and genomic medicine industries, as well as the business strategies of science-driven companies.
Executive Summary
- Illumina was founded in 1998 around microarray technology and transformed itself into an NGS-focused company through its acquisition of Solexa in 2007.
- Its success was driven not only by sequencing-by-synthesis (SBS) technology, but also by the development of an integrated ecosystem encompassing instruments, reagents, library preparation, and bioinformatics.
- The rejection of Roche's acquisition proposal, the abandoned acquisition of PacBio, and the acquisition and subsequent divestiture of GRAIL illustrate the evolution of Illumina's capital allocation strategy and competitive environment.
- Since 2024, Illumina has been rebuilding its core business following the GRAIL separation while expanding into multiomics, including single-cell analysis and proteomics.
- Illumina's corporate history offers an important case study of how a company that establishes a scientific technology as an industry-wide platform seeks new growth opportunities as its core business matures.
1. Introduction: What Kind of Company Is Illumina?
Illumina is a genomics technology company founded in San Diego, California, in 1998. Today, it provides critical infrastructure for genomic science and genomic medicine worldwide.
One of the most interesting aspects of its history is that Illumina was not originally founded to commercialize next-generation sequencing (NGS), the technology that now defines its business.
At its founding, Illumina primarily focused on genetic variation analysis using microarray technology. Sequencing by synthesis (SBS), which became the foundation of its sequencing business, originated at a separate company called Solexa, founded in Cambridge, United Kingdom.
Illumina acquired Solexa in 2007 and subsequently became a leading company in the genomics industry by improving, commercializing, and expanding the adoption of that technology. [1][2][3]
Its corporate history can be divided into six major periods.
| Period | Primary Business Focus | Strategic Significance |
|---|---|---|
| 1998–2006 | BeadArray and SNP genotyping | Massively parallel genomic analysis |
| 2007–2012 | Solexa integration and NGS growth | Transition from microarrays to sequencing |
| 2013–2017 | HiSeq, MiSeq, NovaSeq, and clinical applications | Industrialization of large-scale whole-genome sequencing |
| 2018–2020 | DRAGEN and the proposed PacBio acquisition | Expansion from sequencing instruments into bioinformatics and technology portfolios |
| 2021–2024 | GRAIL acquisition, regulatory disputes, and separation | Failed vertical integration from genomics infrastructure into diagnostics |
| 2024–2026 | NovaSeq X, single-cell analysis, and proteomics | Reinforcement of the core business and expansion into multiomics |
An important conclusion emerges from this history: Illumina's competitive advantage cannot be explained solely by the quality of its sequencing chemistry.
Its long-term success has depended on building an integrated ecosystem encompassing instruments, reagents, library preparation, bioinformatics software, manufacturing capabilities, customer relationships, and connections to the academic research community.
At the same time, the PacBio and GRAIL acquisition attempts illustrate the difficulties that a dominant technology platform provider can encounter when expanding into adjacent markets.
The following sections examine both what happened during each stage of Illumina's development and what those events meant from a business strategy perspective. Strategic interpretations are distinguished from historical facts and are based on publicly available information.
2. The Founding Years: What Problem Was Illumina Created to Solve? (1998–2006)
2-1. Background to the Company's Founding
Illumina was established in April 1998 with the involvement of the following individuals:
- David Walt: Inventor of the foundational technology
- Larry Bock (CW Group): Venture capital and commercialization
- John Stuelpnagel: Early management and business development
- Anthony Czarnik: Scientific technology and commercialization
- Mark Chee: Development of genetic analysis technologies
David Walt was particularly important as the scientific founder who developed the random bead array technology underlying Illumina's original business.
A chemist at Tufts University, Walt later also founded Quanterix, a company focused on ultrasensitive protein detection technologies.
According to a study by the U.S. National Academies, Illumina was founded on an exclusive license to technology developed at Tufts University. [1]
The broader scientific context was the Human Genome Project, which was beginning to generate enormous amounts of sequence information.
For researchers, however, the challenge was not simply to determine genome sequences.
Another major question was:
How could the enormous genetic diversity within human populations be measured rapidly and inexpensively, enabling researchers to investigate associations between genetic variation, disease, and phenotype?
Illumina was founded to address this challenge.
2-2. The First Competitive Advantage: BeadArray
Illumina's original core technology was BeadArray, which enabled massively parallel molecular detection by arranging microscopic beads in large numbers of wells.
Conventional microarrays generally relied on immobilizing probes at predefined positions on a substrate.
Illumina's approach instead used self-assembled arrays of numerous beads carrying probes, with the goal of producing high-density analytical platforms with reproducible performance.
The essential engineering concept was to combine microfabrication and chemical reactions to conduct large numbers of measurements in parallel and then read out the resulting signals at scale.
This approach has a strong conceptual connection to Illumina's later sequencing business.
2-3. Early Products and Commercial Development
| Year | Product or Event | Significance |
|---|---|---|
| 2001 | Oligator and Sentrix Array Matrix | Commercialization of oligonucleotide production and parallel SNP analysis |
| 2002 | BeadLab | Delivery of large-scale genotyping as an integrated system |
| 2003 | Sentrix BeadChip and BeadStation | Expansion of array analysis into research laboratories |
| 2004–2005 | GoldenGate, Infinium, and related products | Scaling of SNP assays and expansion of the product portfolio |
| 2005 | Acquisition of CyVera | Expansion of bead-related technologies |
Illumina also participated in the International HapMap Project and received approximately $9.1 million in funding from the U.S. National Institutes of Health (NIH).
Its relationships with large academic research programs contributed to both technological development and commercialization. [1]
2-4. Capital Formation: From Founding to IPO
| Year | Financing Event | Amount |
|---|---|---|
| 1998 | Venture capital financing | Approximately $8.6 million |
| 1999 | Series C financing | Approximately $28 million |
| 2000 | Initial public offering | More than $100 million |
These figures are approximate amounts based on the National Academies' account of Illumina's early financing. [1]
Illumina went public on NASDAQ in July 2000, approximately two years after its founding.
One notable aspect of this history is that the company successfully raised substantial capital before its product portfolio had fully matured.
Illumina required sustained research and development investment as well as the establishment of sophisticated manufacturing capabilities. Its capital requirements were therefore fundamentally different from those of a typical software startup.
Early access to public capital markets was likely an important enabling factor in the company's subsequent technological development.
2-5. Challenges During the Founding Period
Illumina faced three major business challenges during its early years.
First, it needed to transform a novel laboratory technology such as BeadArray into commercially viable products with reliable and reproducible performance.
Second, the company needed to develop instruments, consumables, assay designs, and software as an integrated system. Without these components working together, customers could not use the technology effectively.
Third, Illumina faced competition from established microarray companies, particularly Affymetrix, which was already a major participant in the large-scale genotyping market.
Illumina responded by emphasizing the massively parallel measurement capabilities and cost competitiveness of its BeadChip technology.
It also lowered adoption barriers by providing genotyping services to research institutions.
In other words, Illumina demonstrated an important strategic principle from an early stage:
Rather than merely selling instruments, it sought to build the infrastructure that enabled researchers to use its technology effectively.
3. The Defining Turning Point: The Acquisition of Solexa (2006–2007)
The most important event in understanding Illumina's corporate history was its acquisition of Solexa.
3-1. What Was Solexa?
Solexa was founded in the United Kingdom in 1998.
Its co-founders, Shankar Balasubramanian and David Klenerman, developed an approach for determining the sequences of enormous numbers of DNA molecules in parallel using fluorescence detection and reversible terminator chemistry.
Balasubramanian, a chemist at the University of Cambridge, played a central role in the invention of SBS technology alongside Klenerman.
Key technological milestones included:
- 1997: Conception of the fundamental approach to parallel DNA sequencing on a solid surface
- 1998: Founding of Solexa
- 2004: Acquisition of cluster-generation-related technology from Manteia
- 2005: Merger with Lynx Therapeutics, bringing additional instrument and software development capabilities
- 2006: Commercialization of the Genome Analyzer
Illumina's own history of sequencing technology describes these developments. [2]
3-2. What Made the Technology Revolutionary?
The strength of the Solexa/Illumina approach came from combining several key technologies.
1. Cluster Amplification
DNA fragments attached to a flow cell are locally amplified through processes such as bridge amplification.
This generates strong fluorescence signals from multiple copies of DNA molecules originating from the same template.
2. Reversible Terminator Chemistry
DNA polymerase incorporates nucleotides in a manner that allows the four bases to be distinguished.
Fluorescence is detected after each cycle, enabling the sequence to be determined one base at a time.
3. Massive Parallelization
Large numbers of clusters are imaged and analyzed simultaneously, enabling throughput orders of magnitude greater than conventional Sanger sequencing.
The essential innovation was not to read individual DNA molecules at exceptionally high speed.
Rather, it was to read enormous numbers of relatively short DNA fragments simultaneously.
This architecture imposed limitations on read length but provided compelling economics for applications such as large-scale resequencing and RNA-seq.
3-3. Why Did Illumina Acquire Solexa?
Illumina announced the acquisition in November 2006 and completed it on January 26, 2007.
The announced transaction value was approximately $650 million, with consideration including approximately 13.1 million Illumina shares. [3]
Strategically, the acquisition was enormously significant.
At the time, Illumina was already a major player in SNP genotyping and gene expression analysis.
However, DNA sequencing had the potential to expand rapidly in scale.
Microarrays generally measure known sequences or variants corresponding to probes designed in advance.
NGS, by contrast, directly determines nucleotide sequences and can identify previously unknown variants.
This suggested that sequencing might eventually replace microarrays in some applications.
Rather than simply defending its existing business, Illumina acquired Solexa's fundamentally different technology and transformed a potential disruption into a major growth opportunity.
3-4. The Strategic Significance of the Solexa Acquisition
Illumina did not merely acquire a finished sequencing instrument.
It acquired a technological foundation consisting of reversible terminator chemistry, cluster generation, instrument design, fluorescence imaging, patents, and teams of scientists and engineers.
These capabilities could support successive generations of sequencing products.
Consequently, the Solexa acquisition should be understood as more than an expansion of Illumina's product portfolio.
It represented a transformation of the company's technological identity.
4. The Expansion of the NGS Market and Product Strategy (2007–2017)
The decade following the Solexa acquisition was the period during which Illumina helped transform NGS from a specialized laboratory technology into a standard tool for large-scale genomics research and clinical research.
4-1. The Evolution of the Product Portfolio
Genome Analyzer / GAII (approximately 2006–2009)
These were early commercial SBS instruments.
The main challenges were commercializing the technology, improving data output, and establishing a community of researchers using the platform.
HiSeq 2000 / 2500 (early 2010s)
High-throughput instruments capable of generating large amounts of sequence data at lower cost.
These platforms supported the expansion of whole-genome sequencing (WGS), exome sequencing, RNA-seq, and related applications.
MiSeq (widely adopted beginning around 2011)
A benchtop sequencing platform that opened new applications in smaller laboratories, including microbial genomics.
MiSeq broadened access to sequencing technology.
HiSeq X Ten (2014)
A large-scale WGS system introduced with the promise of the $1,000 genome.
It became a symbol of the industrialization of population-scale genomics.
NovaSeq 6000 (2017)
A high-performance platform offering increased throughput and operational flexibility.
It addressed the growing demand for large-scale research and testing applications. [2]
Illumina's product strategy during this period went beyond simply improving instrument performance.
By expanding both high-throughput systems and benchtop platforms, the company reached a broad customer base, from major sequencing centers to individual research laboratories.
4-2. How Falling Sequencing Costs Transformed the Industry
| Platform Generation | Human Genome Sequencing Cost Promoted at the Time |
|---|---|
| HiSeq 2000 (2010) | Approximately $10,000 |
| HiSeq X Ten (2014) | Approximately $1,000 |
| NovaSeq (2017) | A potential future $100 genome |
| NovaSeq X (announced in 2022) | A $200 genome under large-scale operating conditions |
These figures represent targets or conditional estimates based on the capabilities announced for each platform.
They do not guarantee the total actual cost per sample.
Actual costs depend on instrument utilization, library preparation, bioinformatics, data storage, quality control, and other factors. [2]
The important point is that cheaper sequencing did not simply lead to lower profit margins.
It expanded the range of research that became economically feasible.
For example, studies involving whole-genome sequencing of only a few dozen individuals had previously required substantial resources.
As sequencing costs fell, studies involving thousands or tens of thousands of individuals became increasingly feasible.
In other words, falling costs helped create a market in which lower prices generated entirely new demand.
4-3. Expansion into Clinical Markets
During the 2010s, Illumina accelerated its expansion beyond research applications and into clinical markets.
Major areas included:
- Non-invasive prenatal testing (NIPT)
- Cancer genomic profiling
- Hereditary disease diagnostics
- Reproductive medicine
- Sequencing platforms used in FDA-regulated applications
A particularly important event was the acquisition of Verinata Health in 2013 for approximately $350 million.
By acquiring Verinata's NIPT-related technologies and intellectual property, Illumina became involved not only in supplying sequencing instruments but also in promoting specific clinical applications.
Nevertheless, Illumina's business at this stage remained primarily focused on supplying instruments, reagents, and related technologies.
Its later acquisition of GRAIL represented a more aggressive step: attempting to own a company that directly provided clinical testing services to patients.
This distinction would eventually become a major source of controversy.
5. Expanding the Business: From Sequencing Instruments to the Entire Workflow (2011–2020)
Illumina's acquisition history reveals a clear strategic direction.
| Year | Acquired Company | Technology | Strategic Purpose |
|---|---|---|---|
| 2007 | Solexa | SBS / NGS | Core sequencing technology |
| 2011 | Epicentre Biotechnologies | Nextera | Library preparation |
| 2013 | Verinata Health | NIPT | Clinical applications and intellectual property |
| 2018 | Edico Genome | DRAGEN | High-speed bioinformatics |
| 2020 | BlueBee | Cloud analysis | Data processing and management |
| 2020 | Enancio | Data compression | Reducing information processing costs |
Early acquisitions focused primarily on strengthening core technologies and assays.
Beginning around 2018, however, investments in bioinformatics and information management became increasingly prominent.
5-1. Epicentre: The Importance of Library Preparation
Illumina acquired Epicentre in 2011, gaining access to Nextera technology, which contributed to more efficient NGS library preparation.
Tagmentation can combine operations related to DNA fragmentation and adapter introduction.
Its value extends beyond reducing hands-on time.
As sample volumes increased, overall workflow throughput depended not only on sequencing instrument speed but also on library preparation complexity, reproducibility, and ease of automation.
By incorporating these processes into its product ecosystem, Illumina strengthened its competitiveness beyond the sequencing instrument itself.
5-2. Edico Genome: Acquiring DRAGEN
In 2018, Illumina acquired Edico Genome for approximately $100 million.
DRAGEN was developed as a technology capable of rapidly performing processes such as sequence alignment and variant calling, using hardware acceleration technologies including field-programmable gate arrays (FPGAs).
As WGS throughput increased, the ability to generate FASTQ files was no longer the only important performance metric.
The time required to transform FASTQ files into meaningful analytical results also became critical.
Through this acquisition, Illumina strengthened its transition from a sequencing instrument manufacturer toward a platform company encompassing bioinformatics.
This direction subsequently contributed to offerings such as DRAGEN, Connected Insights, and Connected Multiomics.
5-3. The Evolution of Illumina's Service and Revenue Models
Illumina's business has never depended exclusively on selling instruments.
Its revenue model can broadly be understood as evolving through four stages.
Stage 1: Measurement Services and Array Products
The company provided large-scale SNP genotyping services, BeadChips, reagents, and scanners.
Stage 2: NGS Instruments and Proprietary Consumables
The business expanded around sequencing instruments, flow cells, SBS reagents, and library preparation kits.
Stage 3: Integrated Workflows
Illumina increasingly combined instruments, reagents, data analysis, cloud platforms, and clinical solutions.
Stage 4: Multiomics Ecosystem
The company is expanding into genomics, single-cell analysis, proteomics, and integrated bioinformatics.
One particularly important feature of this business model is that installed instruments generate recurring demand for consumables.
Once a research facility adopts a sequencing system, it continues purchasing flow cells, reagents, and kits according to its sequencing volume and instrument utilization.
Research protocols, quality control procedures, and bioinformatics pipelines are also optimized around the installed platform.
This creates a foundation for recurring purchases and long-term customer relationships.
6. Major Turning Points in Capital Allocation and M&A
6-1. 2012: Roche's Hostile Acquisition Proposal
In 2012, Roche, the Swiss pharmaceutical and diagnostics company, attempted to acquire Illumina.
Its initial offer of $40 per share was subsequently increased to $44.50 and eventually $51 per share.
Illumina's board rejected the proposals, arguing that they did not adequately reflect the company's potential value.
This episode illustrated Illumina's increasingly important position within the life sciences industry.
Roche operated across both pharmaceuticals and diagnostics, and its interest in Illumina reflected the strategic importance of genomics to the future of diagnostics and personalized medicine.
Illumina, however, chose to remain an independent technology platform company.
The company subsequently achieved substantial growth while maintaining its independence.
Nevertheless, determining whether rejecting Roche's offer maximized long-term shareholder value would require a rigorous comparison of the proposed transaction terms and subsequent realized shareholder returns.
6-2. 2018–2020: The Failed PacBio Acquisition
In 2018, Illumina announced plans to acquire Pacific Biosciences (PacBio) for approximately $1.2 billion.
PacBio's single-molecule real-time (SMRT) sequencing technology differs from Illumina's short-read approach by enabling the sequencing of long DNA molecules.
Long-read technologies are particularly valuable for analyzing structural variants, repetitive sequences, haplotype phasing, and complex genomic regions.
From a technological perspective, combining the two companies offered potential advantages.
However, the United Kingdom's Competition and Markets Authority (CMA) and the U.S. Federal Trade Commission (FTC) raised concerns that the transaction could reduce competition and innovation in the NGS market.
The acquisition was abandoned in January 2020. [4]
Strategic Significance
Illumina lost an opportunity to acquire a major technology that could complement the limitations of short-read sequencing.
At the same time, the episode demonstrated that Illumina's strong position in the sequencing market had made acquisitions of other sequencing technology companies increasingly difficult under competition law.
This was a structural issue that would appear again in the GRAIL case.
6-3. 2021–2024: The GRAIL Acquisition and Separation
One of the most consequential management challenges in Illumina's history involved GRAIL.
GRAIL developed multi-cancer early detection (MCED) technology that analyzes signals associated with multiple types of cancer, including methylation patterns in cell-free DNA circulating in blood.
Its Galleri product is a blood-based multi-cancer early detection test.
GRAIL originally emerged from Illumina itself.
Illumina participated in establishing GRAIL in 2016, after which the company developed as an independent business supported by outside investors.
In 2020, however, Illumina announced plans to reacquire GRAIL.
The announced transaction involved approximately $8 billion in cash and stock, together with provisions for additional contingent payments.
At the time, Illumina owned approximately 12% of GRAIL on a fully diluted basis.
6-4. Why Did Illumina Want to Acquire GRAIL?
Illumina's core business was supplying sequencing instruments and reagents to research institutions and diagnostics companies.
GRAIL, by contrast, used sequencing technology to provide clinical testing services.
By owning GRAIL, Illumina could potentially participate directly in the growing market for cancer early detection rather than benefiting only from increased demand for NGS instruments and consumables.
This represented vertical integration from sequencing infrastructure into clinical diagnostics.
6-5. Why Did the Acquisition Become Controversial?
Regulators were concerned that Illumina's ownership of GRAIL could disadvantage competing MCED developers.
Potential areas of concern included sequencing technology supply terms, pricing, technical support, and access to information.
An important distinction exists between the PacBio and GRAIL cases.
The PacBio acquisition primarily involved a horizontal competition issue: the proposed combination of companies operating in sequencing technology markets.
The GRAIL acquisition involved a vertical competition issue: an upstream supplier of sequencing technology acquiring a downstream clinical testing company.
6-6. Timeline of the GRAIL Acquisition and Separation
September 2020: Acquisition Announced
Illumina announced its proposed acquisition of GRAIL in a transaction valued at approximately $8 billion.
August 2021: Acquisition Completed
Illumina completed the transaction while regulatory reviews were ongoing in the United States and Europe.
2022–2023: Regulatory Conflicts Intensified
The European Commission issued a decision prohibiting the acquisition, while the U.S. FTC also sought the divestiture of GRAIL. [5]
2023: Conflict Between Shareholders and Management
Activist investors, including Carl Icahn, criticized the company's strategy.
Major changes followed in Illumina's leadership and board of directors.
June 2024: GRAIL Separation
GRAIL became an independent publicly traded company listed on NASDAQ.
Illumina retained a 14.5% ownership interest at the time of separation.
The transaction also became entangled in litigation concerning the European Union's jurisdiction to review the acquisition, making the regulatory process particularly complex.
Nevertheless, the ultimate outcome was that the acquisition was unwound and GRAIL returned to operating as an independent company.
6-7. Management Lessons from the GRAIL Acquisition
The GRAIL case demonstrated that acquiring a foundational technology is fundamentally different from acquiring a downstream company that may also be a customer of the acquirer's platform.
With Solexa, Illumina acquired a new core technology.
With GRAIL, it attempted to acquire a clinical testing company operating within the ecosystem supported by its sequencing platform.
This raised concerns about neutrality toward other customers and competitors and created substantial regulatory risk.
As Illumina's technology became common infrastructure for the genomics industry, the extent to which it could expand into downstream markets became an increasingly important strategic constraint.
7. Leadership Transitions: Who Built and Led Illumina?
Illumina's corporate history becomes easier to understand when changes in leadership are considered alongside shifts in business strategy.
7-1. Jay Flatley (CEO, 1999–2016)
Jay Flatley was a central figure in Illumina's transformation into a global genomics technology company.
He led the Solexa acquisition, the expansion of NGS adoption, and the development of the company's product portfolio.
Flatley became CEO in 1999 and transitioned to Executive Chairman in 2016.
When he joined, Illumina had fewer than 30 employees.
By 2015, annual revenue had reached approximately $2.2 billion, and the company had become a major global life sciences instrument supplier.
This growth was, of course, the collective achievement of Illumina's scientists, engineers, manufacturing teams, sales organization, and other employees.
From a management perspective, however, the decision to acquire Solexa after establishing a position in microarrays was especially important.
It fundamentally changed the company's core technology and future trajectory.
7-2. Francis deSouza (CEO, 2016–2023)
Francis deSouza joined Illumina in 2013 and became CEO in 2016.
He promoted expansion into clinical markets, oversaw business growth during the NovaSeq era, and pursued the acquisition of GRAIL.
During his leadership, Illumina became more deeply involved in emerging markets including cancer diagnostics, population genomics, and clinical testing.
However, the regulatory disputes surrounding GRAIL intensified, as did opposition from shareholders.
In 2023, shareholder activism led by investors including Carl Icahn became a major management issue.
DeSouza resigned as CEO in June 2023.
It would be an oversimplification to attribute his departure exclusively to the GRAIL acquisition.
Nevertheless, confidence in the company's governance and strategic direction was significantly challenged during this period.
7-3. Jacob Thaysen (CEO, September 2023–Present)
Jacob Thaysen previously held leadership positions at Agilent Technologies, overseeing businesses involving analytical instruments, diagnostics, and genomics.
He became Illumina's CEO on September 25, 2023.
Since then, he has overseen the separation of GRAIL and efforts to improve profitability and restructure Illumina's genomics and multiomics businesses.
Thaysen was neither an Illumina founder nor an inventor of SBS technology.
Instead, he brought extensive experience managing large analytical instrument and diagnostics businesses.
His appointment suggests that Illumina's management requirements had expanded beyond driving technological innovation and rapid growth.
They now also included profitability, customer base management, business portfolio optimization, and capital allocation.
This does not mean that Illumina has ceased to be an R&D-intensive company or that financial management has replaced technology development as its central priority.
Rather, the responsibilities of its leadership have become more complex.
For completeness, co-founder John Stuelpnagel served as interim CEO between the company's founding in 1998 and Flatley's appointment in 1999.
Charles Dadswell served as interim CEO following deSouza's departure in 2023.
8. 2024–2026: Restructuring and the Multiomics Strategy
Following the separation of GRAIL, Illumina has focused on strengthening its core sequencing business while expanding into multiomics. [6]
This can be understood as a shift from competition based primarily on sequencing instrument performance toward competition over how much biological information can be obtained from a single sample.
8-1. Current Core Products
NovaSeq X / X Plus
These platforms target high-throughput WGS, large-scale cohort studies, and clinical genomics.
They incorporate XLEAP-SBS chemistry.
MiSeq i100 / i100 Plus
Announced in 2024, these systems are designed for smaller laboratories.
They aim to simplify operation and reagent management while enabling rapid analysis.
One notable feature of the MiSeq i100 platform is its emphasis on room-temperature reagent storage and shipping.
This represents an improvement not only in instrument performance but also in the broader operational workflow, including cold-chain logistics, reagent management, and turnaround time.
8-2. Expansion into Single-Cell Analysis
In July 2024, Illumina acquired Fluent BioSciences.
Fluent had developed single-cell analysis technology designed to reduce dependence on complex microfluidic instruments.
Illumina positioned the acquisition as part of its multiomics strategy. [6]
An interesting aspect of this move is that Illumina is not merely attempting to increase sequencing throughput.
It is also seeking to expand the types of samples and libraries that can be analyzed using its sequencing platforms.
In applications such as single-cell RNA-seq, analysis of cellular heterogeneity, and characterization of cellular states, sequencing is only one component of the workflow.
Sample preparation, cell isolation, barcoding, and library preparation are also critical.
By incorporating technologies from these upstream stages, Illumina can expand the range of applications for its NGS instruments.
8-3. 2026: The SomaLogic Acquisition and Expansion into Proteomics
On January 30, 2026, Illumina completed the acquisition of SomaLogic's proteomics business. [7]
SomaLogic's SomaScan technology uses aptamers known as SOMAmers to measure large numbers of proteins.
Illumina has announced plans to integrate SomaScan with its sequencing and bioinformatics ecosystem.
The acquired assets included SomaLogic-related businesses held by Standard BioTools.
The transaction involved approximately $350 million in cash, with up to an additional $75 million in contingent milestone payments. [7]
This marks a significant strategic development.
Historically, Illumina's core business has centered on generating DNA and RNA sequence information at scale.
However, genomic sequences alone cannot fully explain protein abundance, protein activity, post-translational modifications, or cellular states.
By incorporating SomaLogic's technology, Illumina aims to establish a broader analytical platform spanning genetic information and protein-level measurements.
For now, this remains a strategic growth initiative.
Whether the SomaLogic acquisition will become a transformation comparable to the Solexa acquisition will depend on the success of technological integration and commercialization.
9. Financial and Capital Structure Evolution
9-1. Revenue Growth Over Time
| Year | Revenue |
|---|---|
| 2000 | Approximately $1.3 million |
| 2015 | Approximately $2.2 billion |
| 2025 | Approximately $4.34 billion |
The 2000 figure is based on the National Academies' historical account, the 2015 figure on Illumina's reported results, and the 2025 figure on Core Illumina revenue.
These figures are intended to illustrate long-term growth. The scope of the business and consolidated reporting changed over time. [1]
A notable trend is that the exceptionally rapid growth of the 2000s and 2010s slowed during the 2020s.
Core Illumina revenue was approximately $4.34 billion in 2025, essentially flat compared with approximately $4.33 billion in 2024.
These figures suggest that Illumina has entered a more mature stage of development, in which its business is increasingly influenced by research funding, capital expenditure cycles, competition, and geopolitical conditions.
9-2. Current Revenue Structure
Illumina's 2025 revenue composition was approximately as follows:
| Revenue Category | Share of Revenue |
|---|---|
| Consumables | 74% |
| Services and other revenue | 15% |
| Instruments | 11% |
These percentages represent the consolidated revenue composition for fiscal year 2025, based on the company's Form 10-K.
This distribution is essential to understanding Illumina's business model.
Most of its revenue comes not from instruments themselves, but from consumables.
Instrument installations establish the foundation for future recurring consumables revenue.
Therefore, the number of sequencing instruments sold is not the only important performance indicator.
Other critical factors include:
- How many instruments are installed and actively operating
- How much sequencing is performed per instrument
- Which applications drive ongoing customer usage
- How smoothly customers can transition to newer instrument generations
These factors influence the company's long-term financial performance.
As of 2025, Illumina reported an installed base of approximately 21,000 instruments and a workforce of approximately 8,600 employees.
9-3. Latest Developments in 2026
Illumina's third-quarter financial results, announced on October 29, 2026, showed signs of improving business performance. [8]
| Metric | Q3 2026 Results |
|---|---|
| Quarterly revenue | Approximately $1.13 billion |
| Year-over-year revenue growth | +4.2% |
| GAAP operating margin | 27.0% |
The company's 2026 full-year revenue guidance, excluding the impact of tariff refunds, was approximately $4.64 billion to $4.66 billion. [8]
The reported operating margin included the effects of tariff refunds, which should be accounted for when evaluating recurring profitability.
In its latest announcement, Illumina attributed support for its performance to NovaSeq X installations and demand from clinical customers.
The full-year revenue guidance is a forecast rather than a reported result.
9-4. Challenges in the Chinese Market
In 2025, the Chinese government placed Illumina on its unreliable entity list.
In March of that year, China announced measures prohibiting the company from exporting genetic sequencing instruments to the Chinese market.
Revenue from the Greater China region declined in 2025.
This episode illustrates that genomic technologies are not merely subjects of scientific research or commercial activity.
They are also closely connected to national strategy, economic security, and data sovereignty.
For Illumina, reducing dependence on the Chinese market while developing growth opportunities in other regions has become an important challenge.
10. Major Challenges and How Illumina Responded
The company's history can be summarized from the perspective of the challenges it encountered and the strategies it pursued.
| Challenge | Response | Assessment as of 2026 |
|---|---|---|
| Risk that NGS could replace parts of the microarray business | Acquisition of Solexa | Major success |
| Sequencing throughput and cost limitations | Continuous development of HiSeq, NovaSeq, and related platforms | Long-term success |
| Increasing sample preparation and computational demands | Acquisition of Nextera, DRAGEN, and cloud technologies | Expanded the business foundation |
| Maintaining corporate independence | Rejection of Roche's acquisition proposals | Independence maintained |
| Expanding into long-read sequencing | Proposed acquisition of PacBio | Abandoned due to regulatory concerns |
| Direct participation in clinical testing markets | Acquisition of GRAIL | Divestiture following regulatory disputes |
| Slowing growth as the business matured | NovaSeq X and workflow improvements | Recovery still in progress as of 2026 |
| Expansion into multiomics | Acquisitions including Fluent and SomaLogic | Long-term outcome remains to be determined |
| Geopolitical risks in China | Regulatory engagement and growth efforts in other regions | Some issues remain unresolved |
10-1. Comparing Solexa, PacBio, and GRAIL
Comparing the Solexa, PacBio, and GRAIL transactions highlights how the difficulty of expanding through M&A changed as Illumina grew.
| Transaction | Period | Primary Strategic Objective | Outcome |
|---|---|---|---|
| Solexa | 2007 | Acquire a new core technology | Completed |
| PacBio | 2018–2020 | Integrate competing and complementary technologies | Abandoned |
| GRAIL | 2021–2024 | Integrate into downstream diagnostics | Divested |
This comparison suggests that as a company becomes larger and develops a stronger market position, competition law can increasingly restrict its ability to expand through acquisitions.
11. Why Was Illumina Able to Build Such a Strong Competitive Position?
Illumina's success can be examined from both technological and management perspectives.
11-1. Amplifying Core Technology Through Manufacturing Capabilities
The strength of the SBS technology inherited from Solexa was undoubtedly important.
However, a promising scientific technology alone is insufficient to build a global business.
Illumina continuously improved flow cells, reagents, optical systems, data acquisition, and bioinformatics software.
Through these improvements, it developed an industrial system capable of producing large quantities of high-quality sequencing data.
Its competitive advantage therefore appears to arise not merely from individual inventions but from integrating multiple technical components and improving them continuously.
11-2. An Ecosystem That Becomes Stronger as Adoption Expands
As more sequencing instruments are installed, the number of research protocols, bioinformatics tools, validation datasets, and trained specialists associated with those platforms increases.
When new experimental methods are developed using Illumina platforms, other researchers gain additional incentives to adopt the same technologies.
This is not a network effect in the strictest sense.
Nevertheless, the expanding ecosystem represents an important source of competitive advantage.
11-3. Developing Research and Clinical Applications in Parallel
Illumina has supported the adoption of NGS in academic research while also facilitating the translation of research discoveries into clinical testing and medical applications.
Under this model, new research applications can eventually develop into significant clinical markets.
However, clinical markets present challenges that differ from those of academic research.
These include regulation, quality management, reimbursement systems, and the generation of clinical evidence.
The company's future growth will depend in part on how effectively it can support the transition from research applications to routine clinical use.
11-4. The Competitive Landscape Ahead
Illumina now faces competition across several technological dimensions beyond conventional short-read sequencing.
These include:
- Long-read sequencing technologies from companies such as PacBio and Oxford Nanopore
- Competition in sequencing markets from companies such as Element Biosciences and MGI
- Specialized companies in single-cell and spatial omics
- Proteomics technologies based on mass spectrometry, aptamers, and antibodies
- Advances in cloud computing and artificial intelligence for genomic analysis
These technologies are not necessarily direct substitutes within a single market.
For example, short-read and long-read sequencing can be complementary depending on the application.
In multiomics, combining different measurement technologies may create additional value.
Consequently, Illumina's future growth will require maintaining improvements in short-read sequencing cost and performance while expanding the types of biological information its customers can obtain.
12. Conclusion: What Illumina's Corporate History Teaches Us
Five particularly important lessons emerge from Illumina's approximately 28-year history.
12-1. A Company's Founding Technology Does Not Necessarily Become Its Long-Term Core Technology
Illumina began with microarrays and subsequently transformed its business by acquiring Solexa's sequencing technology.
This transition can be understood as a strategy that prioritized anticipating the future of the genomics market over simply preserving the company's existing technological base.
12-2. Acquiring a Foundational Technology Is Not Enough: Commercialization and Large-Scale Manufacturing Matter
Illumina's competitive advantage was not based solely on the invention of SBS technology.
It also depended on developing that technology into reliable, accessible, and increasingly cost-effective products.
Transforming a scientific invention into a practical platform requires the integration of chemistry, optics, mechanical engineering, manufacturing, bioinformatics, and other disciplines.
12-3. Integrating Hardware, Consumables, and Software Can Create a Powerful Recurring Revenue Model
The fact that consumables accounted for 74% of Illumina's revenue in 2025 illustrates the structure of its current business.
Long-term sustainability depends not simply on the installed instrument base but also on the research methods, analytical workflows, and software environments that support continued instrument use.
12-4. Expansion into Downstream Markets Creates Challenges Around Neutrality and Competition Law
GRAIL is a particularly clear example, with an outcome fundamentally different from that of Solexa.
When a company providing common infrastructure for an industry acquires a business operating on that infrastructure, the consequences for customer relationships and fair competition cannot be ignored.
12-5. Future Growth Requires Expanding the Types of Biological Information That Can Be Measured
Illumina is seeking to expand beyond nucleotide sequence generation into single-cell analysis, proteomics, and integrated bioinformatics.
This suggests a transition toward competition based not only on sequencing cost and throughput but also on the breadth of biological information that can be generated and interpreted.
Illumina's history is therefore more than a story about the widespread adoption of NGS.
It is a case study in how a company can transform scientific technology into common industrial infrastructure—and how that company subsequently searches for new growth opportunities once its original market begins to mature.
As of 2026, Illumina is in a very different position from the company that established its leadership in NGS through the Solexa acquisition.
It now faces the challenge of maintaining a mature and substantial core business while developing the next engines of growth.
References
[1] National Research Council, "Illumina," The Role of the National Science Foundation in the Innovation Ecosystem, National Academies Press. https://www.ncbi.nlm.nih.gov/books/NBK11460/
[2] Illumina, "History of Sequencing," Illumina. https://www.illumina.com/science/technology/next-generation-sequencing/illumina-sequencing-history.html
[3] Illumina, "Annual Report on Form 10-K," 2006. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1110803/000093639207000158/a27675e10vk.htm
[4] UK Competition and Markets Authority, "Illumina and PacBio abandon merger," 2020. https://www.gov.uk/government/news/illumina-pacbio-abandon-merger
[5] U.S. Federal Trade Commission, "Illumina, Inc. and GRAIL, Inc., In the Matter of," FTC Case No. 201-0144. https://www.ftc.gov/legal-library/browse/cases-proceedings/201-0144-illumina-inc-grail-inc-matter
[6] Illumina, "Illumina 2024 Strategy Update," 2024. https://www.illumina.com/company/news-center/press-releases/2024/ad8bccba-d792-4ec9-8815-7c20af28cb43.html
[7] Illumina, "Illumina Completes Acquisition of SomaLogic," 2026. https://investor.illumina.com/news-releases/news-release-details/illumina-completes-acquisition-somalogic
[8] Illumina, "Third Quarter 2026 Financial Results," 2026. https://investor.illumina.com/static-files/425680f5-fad9-4b9e-af2b-d863bdaa9ac9
Research cutoff date: November 3, 2026. Financial figures are generally presented in U.S. dollars. Historical facts, targets announced by the company at the time, and strategic interpretations based on publicly available information are distinguished throughout the article.